LITE · 425

Filing note · 425 · filed 2026-11-02 · Lumentum Holdings Inc.

Lumentum Holdings Inc. [[LITE]] — Proposed $115 Billion Marvell Stock Merger, with $1B+ in Targeted Synergies

Filing Summary Lumentum and Marvell have agreed to a fixed-ratio, all-stock merger: Lumentum common shareholders would receive 4.500 Marvell [[MRVL]] shares per Lumentum share. The transaction materials cite an implied value of about $1,132 per Lumentum share, a 23.9% premium to the October 28, 2026 unaffected closing price, and roughly $115 billion enterprise value; the value delivered will fluctuate with Marvell’s share price. The strategic case rests on combining their AI-data-center connectivity businesses and achieving more than $1 billion in annual run-rate synergies, which remain projections rather than realized benefits.

Terms & Mechanics - Consideration and ownership: All-stock consideration at 4.500 Marvell shares per Lumentum common share; Lumentum shareholders are expected to own about 33% of the combined company, with Marvell shareholders holding about 67%. The $1,132 implied value and $115 billion enterprise value are based on cited unaffected prices, not a fixed cash payout. - Preferred shares and awards: Lumentum Series A preferred holders generally receive Marvell common shares based on their existing conversion entitlement and the exchange ratio; eligible holders may elect Marvell Series B preferred shares under specified conditions. Lumentum equity awards generally convert into Marvell awards, with specified treatment for performance units and director awards. Final preferred elections and resulting issuance are not disclosed in filing materials. - Termination payments: In specified circumstances, Lumentum may owe Marvell $2.9 billion; Marvell may owe Lumentum $5.8 billion in specified circumstances, plus a separate $3.2 billion regulatory termination fee in defined regulatory-failure scenarios. - Approvals and timing: Closing requires both companies’ shareholder approvals, regulatory clearances, an effective Form S-4, Nasdaq listing approval, and other conditions. The stated expected closing is first-half 2028; the agreement’s outside date is November 1, 2027, with specified regulatory-delay extensions through August 1, 2028. - Contextual delta: The supplied same-day context filings are customer and supplier communications, not earlier deal terms. No change from a prior merger proposal or agreement is disclosed in the provided materials.

Strategic & Capital Implications The combination would pair Marvell’s custom silicon, switching, and connectivity capabilities with Lumentum’s lasers, optical transceivers, optical circuit switching, and photonics manufacturing. Management argues this could support integrated solutions across AI data-center networks; it cites a $550 billion addressable market, more than $1 billion in annual run-rate synergies—primarily from cost of goods sold—and first-year post-close non-GAAP EPS accretion for Marvell. These are targets and forecasts, not demonstrated results; the materials do not quantify expected integration costs or a detailed synergy timetable.

For Lumentum holders, the fixed exchange ratio provides ongoing ownership in the combined company but does not lock in a dollar value. The long approval period leaves exposure to Marvell’s share-price movement, regulatory delay, customer and employee retention, integration execution, and failure to achieve projected synergies. The sizable termination fees may discourage abandonment or competing transactions, but do not remove closing risk.

Next Catalysts - Form S-4 filing, SEC review and effectiveness, and distribution of the joint proxy statement/prospectus. - Lumentum and Marvell shareholder votes, including Marvell approval of the share issuance and charter amendment. - HSR and other required regulatory reviews, and Nasdaq listing approval for merger shares. - Lumentum preferred-holder elections and subsequent disclosure of the resulting Series B issuance. - Progress toward the expected first-half 2028 close and the contractual outside date and extensions. - Further detail on integration costs, synergy timing, and whether the projected EPS and operating benefits remain achievable.

Follow-ups

#### You: Is there a way to buy LITE and short MRVL to add some risk mitigation to this deal?

Yes. For the common-stock portion of the deal, a simple exchange-ratio hedge would be to buy 1 LITE share and short 4.5 MRVL shares. If the merger closes on the stated terms, the 4.5 MRVL shares received for that LITE share could cover the short, reducing exposure to changes in MRVL’s share price while leaving the deal’s closing-value spread as the main exposure.

That is not a risk-free hedge: if the deal fails or is delayed, LITE could fall while MRVL rises, hurting both legs. Borrow availability and fees, margin calls, dividends, and price movements before closing can also affect results. The filing’s preferred-share elections and award conversions have separate mechanics, so the 4.5-to-1 hedge applies to LITE common shares—not every security or position.

[Generated on Edgar Tracker · edgartracker.com · AI summary · GPT 6 luna · selected parts]